Back to search
Publication

Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties.

Abstract

This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II ("difficult to treat") tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women.

More information

Type
Journal Article
Author
Talwar GP
Gupta JC
Mustafa AS
Kar HK
Katoch K
Parida SK
Reddi PP
Ahmed N
Saini V
Gupta S
Year of Publication
2017
Journal
Biologics : targets & therapy
Volume
11
Number of Pages
55-63
Language
eng
ISSN Number
1177-5475
DOI
10.2147/BTT.S128308
Alternate Journal
Biologics
Publication Language
eng